New cocktail of drugs takes on tough pancreatic cancer

NCT ID NCT07671339

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing whether adding an experimental cancer vaccine (ELI-002 7P) and an immunotherapy drug (tislelizumab) to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with a specific type of pancreatic cancer that has a KRAS mutation. The study will enroll 20 patients whose cancer is still confined to the pancreas and can potentially be removed by surgery. The main goal is to check for serious side effects, while also seeing how well the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mFOLFIRINOX (chemotherapy), ELI-002 7P (cancer vaccine), and tislelizumab (immunotherapy)
What this could lead to: If successful, this could point toward a more effective treatment approach for pancreatic cancer that may improve surgical outcomes and long-term control.
What could go wrong: This is a very early Phase 1 trial with only 20 participants, focused primarily on safety. The combination may cause significant side effects and may not prove effective against the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activites)
RECRUITING

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.